Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5200-0.0200 (-3.70%)
At close: 02:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5400
Open0.5200
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.5010 - 0.5350
52 Week Range0.4700 - 5.0000
Volume96,090
Avg. Volume71,333
Market Cap20.166M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-0.1510
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CYTRX CORP
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Business Wire

    CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

    LOS ANGELES, November 30, 2021--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today issued a presentation on Centurion BioPharma Corporation's ("Centurion BioPharma") plans for a world-class cancer center in Las Vegas, Nevada. Centurion BioPharma is a private wholly-owned subsidiary that focuses on advancing the Company's proprietary, albumin bindin

  • Business Wire

    CytRx Comments on Quarterly Results and Recent Strategic Initiatives

    LOS ANGELES, November 12, 2021--CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the quarter ended September 30, 2021. In addition, CytRx recapped corporate developments as well as matters pertaining to its agreements with ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio") and Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme"). T

  • Business Wire

    CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

    LOS ANGELES, November 09, 2021--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Centurion BioPharma Corporation ("Centurion BioPharma"), a private wholly owned subsidiary that focuses on advancing the Company’s proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates, has been

Advertisement
Advertisement